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Division of Bialopical and Medical Research, Arponne National Laboratory, Arponne. Illinois 
Since phenobarbital is known to induce drug-metabolizing enzymes and to alter the 
effectiveness of certain carcinogens, its influence on 7,12-dimethylbenz [a]anthracene 
(DMBA)-induced skin carcinogenesis has been examined. Skin tumor development was 
studied in groups of hairless mice treated with repeated applications of DMBA and 
maintained on either a control diet or one supplemented with 0.05% phenobarbital. The 
feeding of phenobarbital concurrently with the application of DMBA delayed the appearance 
of papillomas initially, but the suppression of the ultimate tumor yield was variable. and 
appeared to be dependent on the dose of the carcinogen and the age-dependent toxicity 
response of the mice. Phenobarbital was ineffective when DMBA was applied in sufficiently 
large amounts to elicit marked cutaneous damage. or when dietary phenobarbital was started 
1 week after the cessation of the DMBA treatment. Although the dietary administration of 
phenobarbital caused an apparent decrease in the final incidence of papillomas and 
sarcomas, the feeding did not appear to modify the macroscopic skin response or change the 
incidence of carcinomas. 
Studies have shown that a variety of tissues have 
inducible microsomal enzyme systems which are 
implicated in the metabolism of polycyclic hydro-
carbons. Although there are apparent species and 
tissue differences in the expression of these sys-
tems, many of the microsomal enzyme inducers. 
benzo[a]pyrene and flavones. for example. have a 
generalized effect. inducing microsomal aryl hy-
drocarbon hydroxylase (AHHl and altering the 
tumor response in various tissues. including liver. 
lung. and skin [1-:3]. 
Previous studies have shown that phenobarbital. 
a known inducer of hepatic microsomal drug-me-
tabolizing enzymes. reduced hepatic tumorigenesis 
induced by 2-acetylaminofluorene (AAF) when 
the two agents were fed simultaneously to rats 
[4]. Pretreatment with injections of phenobarbi-
tal also reduced the number of lung tumors in-
duced by urethan in mice [5]. On the other hand, 
the incidence o( AAF-induced liver tumors in rats 
was significantly increased when dietary pheno-
barbital was initiated after the cessation of the 
AAF feeding. and phenobarbital was fed for 100 
days or longer [6). Similarly, dietary phenobarbi-
tal enhanced the appearance of spontaneous liver 
tumors in mice [7 ]. It is not known whether this 
enhancing effect is specific to the liver. 
The present experiments were designed to deter-
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mine whether dietary phenobarbital given prior or 
concurrent to applications of DMBA would reduce 
the oncogenic effects in the skin and. secondly. 
whether protracted administration of phenobarbi-
tal after the DMBA treatment would enhance the 
incidence of tumors. 
MATERIALS AMJ METHODS 
Female, hairless HRS/.1/Anl mice were used in all of 
the experiments. This inbred strain of mice was caesar-
ean derived and has been maintained at Argonne Na-
tional Laboratory since 1966. The animals were housed, 
10 per cage, at 25"C in fluorescent-lighted rooms (12 hr 
light; 12 hr dark). and were fed a standard laboratory diet 
prior to the experiment. While the incidence of lymphoid 
leukemia is high, 25 to 40'k in untreated animals. 
epidermal tumors are infrequent, with only 2 animals 
within a control group of 76 mice developing skin lesions, 
a papilloma and a fibrosarcoma, during a normal life-
span. 
The experimental reg-imens are shown in Figure 1. 
Thirty mice were assigned to each experimental group an 
a random but similar age distribution basis. In the initial 
series of experiments, the animals were 24 to 26 weeks of 
age at the time of the first of either 6 i Group Ia. !b) or 12 
(Group !c. ldl weekly applications of 250 l'g DMBA. In a 
second series, the mice were 10 to 12 weeks of ag-e at the 
time of the first of 12 weekly applications of either 250 l'g 
(Group !Ia. lib) or 100 l'g DMBA (Group lie. lid). At 
different times with respect to the initial application of 
DMBA. each group of mice was placed on either a 30o/c 
casein pelleted control diet (General Biochemicals, Inc .. 
Chagrin Falls. Ohio) nutritionally adequate in the other 
dietary components, or one that was additionally supple-
mented with 0.05% phenobarbital. The mice were main-
tained on these diets ad libitum throughout the experi-
ment. 
7,12·Dimethylbenz [a ]anthracene iDMBA, Eastman 
Organic Chemicals, Rochester. New York) was dissolved 
258 
April1975 EFFEcr OF PHENOBARBITAL ON DMBA-INDUCED SKIN TUMORS 259 
[
!a-Control <fie! ---H---> 
[J?{i}~,J:~:!l tss weebl 
I.b-PI'tenoborb-itol die-t -f~---+ 
'56 Weeks) 
~;~~~~~~~:::~g~~~-~:~:A~i~~\..:,;:w:~,=·=::;-----f,_ (40 Weeks.) 
~~ll~b~~~e:no;.b:a~r~;.to~l~d~IO;t::~----ff---+ 
r---r;2_I~~c~~;~~:~~~~:~~d~_:~:;1_~:1w:e:ek::~----ff---+ 
Cnd-PIJ.enoborbifaj d1et If___., 
~c_l___J_! _IL.J!__[_I __j_l _j!__[_! ___J_I _jiL.ll __j__J!L.ll __L_j__L_f f--
1 2 3 4 5 6 7 8 9 1011 12 
TIME (Weeks) 
FIG. 1. Experimental procedure. 
(40 Weeks.) 
in acetone, and 0.1 ml of the solution was applied 
topically by means of a micropipette and distributed over 
approximately a 10 cm 2 area on the backs of the mice 
with a No. 3 camel's hair brush. The sclutions were made 
monthly usin!( rea!(ent-grade DMBA and solvent and. 
during the period of use, the solutions were refrigerated in 
dark bottles. For all experiments, mice were painted 
during the same period of the day. with the same stock 
solutions of the carcino!(en. 
Durin!( the first 20 weeks of the experiment all of the 
animals were inspected weekly for the appearance of skin 
tumors. Thereafter, papillomas and other tumors were 
recorded on a semimonthly basis for a total of either ~6 
weeks (Group]), or 40 weeks (Group Ill from the time of 
the initial DMBA treatment. Pedunculated. firm masses 
which projected about I to 2 mm were considered 
papillomas and recorded when they were about I mm in 
size, occurred within the treated area. and persisted for 2 
successive weeks. On microscopic examination these 
masses showed thickened and folded !aye" of epithelium 
covering the characteristic elongated papillae which 
formed the stalk. All mice were necropsied. and tumors 
as well as about IO'k of the papillomas with typical 
appearance, and ali of those which differed macroscopi-
cally from the characteristic lesion, were examined histo-
logically. Chi squares were calculated by use of the null 
hypothesis that the incremental appearance and the 
frequency distribution of tumors between dietary groups 
would be the same. with the probability of fit at the 5r; 
level. In addition. differences in the cumulative incidence 
of tumors between groups were determined by the Stu· 
dent"s 1-test, with log transformation' to approximate a 
normal distribution. 
RESULTS 
The percentage of tumor-bearing animals in 
each treatment group, with respect to the time of 
the initial application of DMBA, is shown in 
Figure 2. There were no differences in the survival 
rates of animals within each of the groups. and the 
Poisson distribution provided a satisfactory de-
scription of the frequency distribution of tumors 
among animals within groups throughout the pe-
riod of observation. The cumulative number of 
'The values were all increased bv an increment of I to 
adjust for zero values. · 
epidermal tumors observed in each dietary group, 
with respect to the time of the initial DMBA treat-
ment, is shown in Figure 3. These values reflect 
the net number of tumors observed during each 
of the observation periods. 
The phenobarbital-supplemented diet appeared 
to delay the appearance of papillomas initially. 
wben the diet was started 1 week after a series of 6 
weekly applications of DMBA (Group Ibi. but not 
at a statistically significant level when compared 
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FIG. 2. Effects of dietary phenobarbital on the inci-
dence of DMBA-induced skin tumors. Each group con-
sisted of 30 mice which were treated with either 6 weeklv 
applications of 250 l'g DMBA ll>--~1. or l2 weekly 
applications of 250 l'g 10- -01 or JOO l'g (0--0) 
DMBA. Animals in experimental groups Ia. b. c. and 
d were placed on either a 30'1 casein diet I open symbols). 
or one that was supplemented with 0.05S phenobarbital 
(closed svmbols). from the 7th week after the initial 
DMBA treatment. Mice in Group II were fed the respec-
tive diets beginning 2 weeks before the onset of the 
DMBA treatment. 
FIG. 3. Tumor yield in mice induced by repeated 
applications of DMBA and fed a control or phenobarbi-
tal-supplemented diet. The conditions of the experiments 
and the respective symbols are identical to those de-
scribed in Figure 1. The data for the skin tumors include 
papillomas. carcinomas. and sarcomas. with papillomas 
the predominant lesion. 
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to the frequency distribution of tumors in animals 
maintained on the control diet (Group Ia). The 
regression of papillomatous lesions, and the rate of 
loss were comparabie in the two dietary groups. 
The final cumulative incidence was 36.4% (Group 
Ia, 20/55) and 37.7% (Group Ib 20/53). On the other 
hand, the dietary administration of phenobarbital 
concurrently with the 7th application ofDMBA, in 
a series of 12 weekly applications, significantly 
reduced the incremental appearance of skin tu-
mors during the first week of combined treatment 
(Tab. I). Thereafter, the frequency of tumors in the 
phenobarbital group (ld) was reduced compared to 
the incidence in the control group (lc) during the 
next 5 successive weekly intervals, i.e., from the 
8th week through the 13th week after the initial 
DMBA treatment, and on an equal probability 
basis p = (1/2)-•. Subsequently, the incremental 
appearance of papillomas in the two dietary groups 
was comparable. Statistical analysis of the cumu-
lative incidence of epidermal tumors revealed that 
the yield of tumors was significantly decreased in 
mice maintained on the phenobarbital-supple-
mented diet from the lOth week after the initial 
DMBA treatment (Tab. II) throughout the dura-
tion of the experiment. Likewise the final number 
of papillomas and sarcomas was significantly lower 
in the group of animals maintained on phenobarbi-
tal, whereas the frequency of carcinomas was 
comparable in the two dietary groups (Tab. III). 
Regressions of outgrowths, which were presumed to 
be papillomas, occurred throughout the period of 
observation and the frequencies of these lesions 
were comparable in both dietary groups, namely, 
18% (Group Ic, 25/140) and 21% (Group Id, 19/89). 
These values represent the gross number of papil-
lomas, carcinomas, and sarcomas observed in the 
treated areas of the epidermis throughout a 40-
week interval after the initial DMBA treatment. 
The younger, 10- to 12-week-old animals, were 
markedly more sensitive to the carcinogenic treat-
ment, and 12 weekly applications of 250 ,.g DMBA 
TABLE I. Frequency distribution of the increment in the 
number of shin tumors observed in mice I weell after 
the initiation of either a control diet or a phenobarbital-
supplemented diet, when the diets were started con-
currently with the 7th, in a series of 12 weekly applica-
tions of 250 ,.g DMBA 
Increment in 
the number ot 
tumors 
0 1 2 3 
Groupid N =30 25 5 - -
(Phenobarbital diet) M = 0.40 
Groupie N = 30 20 5 5 -
(Control diet) M = 0.87 
N = number of mice. 
M = mean number of tumors per mouse. 
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TABLE II. Cumulative frequency of distribution of skin 
tumors in mice maintained on a phenobarbital-supple-
mented diet as compared to a control diet, 10 weeks 
after the initial application of DMBA, and a treatment 
described in Table I 
Although the Poisson distribution provided a satisfac-
tory description of the frequency distribution of tumors, 
at some weekly intervals deviations at the 0.05 critical 
limit were noted, for example, at the lOth, 12th, 14th, and 
17 -20th week in the case of Group lc, and with respect to 
Group Id the lOth, 19th, and 20th week. These exceptions 
were followed by intervals in which the observed frequen-
cies conformed to the Poisson distribution, and have been 
attributed to a limited sample size. 
Numb<.T of 
tumors 
0 1 2 3 4 5 ~6 
Groupld ,j N =30 22 4 1 1 1 1-
(Phenobarbital diet) M = 0,60 
I 
Groupie N =30 1£ :> 4 2 2 1 2 
(Control diet) M= 1.47 
N = number of mice. 
M = mean number of tumors per mouse. 
TABLE III. The final distribution of papillomas and 
sarcomas in animals maintained on a control diet (!c) 
and a phenobarbital supplemented diet (ld), with 
treatment as described 
Group ld 
(Phenobarbital 
diet) 
Papillomas 
Sarcomas 
Groupie 
(Control diet) 
Papillomas 
Sarcomas 
N = 28 
M = 1.86 
N ~ 28 
M = 0.18 
N = 27 
M = 3.30 
N = 27 
M 0.41 
N = number of mice. 
M = mean number of tumors per mouse. 
caused inflammation and ulceration in all animals 
irrespective of the diet. Under these conditions 
phenobarbital had no significant effect on the 
appearance or development of skin tumors. At the 
15th week subsequent to the initial DMBA treat-
ment all of the animals bore multiple papillomas 
and other epidermal tumors. A major portion of 
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the animals within each group was debilitated with 
severe ulceration and large tumors, and the ex-
periments were terminated. In the younger ani-
mals treated with 12 weekly applications of 100 
f.l.g of DMBA, there was a significant decrease in 
the incidence and frequency distribution of pap-
illomas in the phenobarbital dietary group (lid) 
compared to that observed in the control group 
(lie}. These differences were statistically signifi-
cant during the first 15 weeks after the initial 
DMBA treatment. with the cumulative tumor 
yield for the 15th week shown in Table IV. Subse-
quently, the weekly incremental appearance, and 
the cumulative number of papillomas, carcinomas, 
TABLE IV. The cumulative frequency distribution of skin 
tumors observed 15 weeks after the initial application 
of DMBA, in animals placed on a 0.05% phenobarbi-
tal-supplemented diet or a control diet, which were 
initiated 2 weeks prior to the start of 12 weekly appli-
cations of 1()() IJ.lf DMBA 
Number of 
tumors 
0 1 2 3 
Group lid N ~ 30 26 3 1 (Phenobarbital diet) M 0.27 -~ 
Group He N ~ 30 19 7 3 1 (Control diet) M ~ 0.67 
N ~ number of mice. 
M ~ mean number of tumors per mouse. 
and sarcomas were comparable in both dietary 
groups. A similar number of outgrowths regressed 
in the two dietary groups with the total incidence 
6.3% (Group He, 8/127) and 7.7% (Group Ild, 
10/130) of the gross number of lesions observed 
throughout the 40-week interval. 
Apart from the differences in the appearance of 
papillomas, and irrespeetive of the sequence of the 
treatment, phenobarbital did not appear to influ-
ence the graded skin response, or significantly 
change the incidence of carcinomas. The initial 
skin changes and the tumor incidence for the 
respective experimental groups 40 weeks after the 
first DMBA treatment, are shown in Table V. The 
tumors recorded as carcinomas were typical exam-
ples of either basal or squamous cell carcinomas, 
and the sarcomas were fibrosarcomas varying in 
the degree of differentiation. with all types exhibit-
ing infiltration in the underlying or surrounding 
tissue. 
DISCUSSION 
The present study showed that the dietary 
administration of phenobarbital prior to and con-
currently with the application of DMBA inhibited 
initially the appearance of papillomas, but did not 
completely eliminate the eventual appearance of 
tumors. Under these conditions the effects pheno-
barbital exerted on the skin appear to be analgous 
to the inhibitory effects observed in liver and lung 
tumorigenesis [4,5]. The mechanism by which 
phenobarbital reduced the incidence of skin tu-
mors is not clear. It is not known precisely what 
TABLE V. The acute skin response and tumor formation initiated by repeated applications of DMBA in 
groups of mice fed a control diet or one supplemented by phenobarbital 
Treatment Final number Survi- Final incidenee of~ Skin response of Unknownt group 
papillomas a 
vorse- Carcinomas Sarcomas 
I a Moderate erythema and slight to 23 ( 10)" 29 3 (3) 7 (5) 2 
moderate desquamation 
Ib Moderate erythema and slight to 26 (12) 26 4 (3) 2 (2) l 
moderate desquamation 
lc Moderate erythema and desquamation; 89 (25) 27 10 (10) 11 (10) 5 
10% focal ulceration 
ld Moderate erythema and desquamation; 52 (24) 28 11 (9) 5 (5) 2 
10% focal ulceration 
Ha Marked erythema and desquamation; all All animals bore multiple papillomas and lesions that 
animals exhibited general dermatitis appeared to be malignant by the 15th week and the 
and ulceration experiments were terminated. No histopathologic 
examination was carried out. 
He Slight to moderate erythema and very 96 (25) 29 15 (13) 6 (5) 2 
slight desquamation 
lid Slight to moderate erythema and very 101 (25) 29 13 (12) 5 (5) 1 
slight desquamation 
"Values shown are the net papilloma count. 
• Number of mice alive when the first carcinomas were observed in the respective treatment groups; initially 30 mice 
were assigned to each group. 
'Malignant-appearing tumors without histologic confirmation, e.g., autolysis or animal missing. 
• The number of tumor-bearing animals is given in parentheses. 
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enzyme systems are involved in the inactivation of 
DMBA or whether phenobarbital is an effective 
inducer of such enzymes in the skin. Recent studies 
suggest that hepatic activation of polycyclic hydro· 
carbons may be a major factor in the production of 
skin tumors [8 ]. If this is the case, it is possible 
that phenobarbital alters the rate of appearance of 
skin tumors by its effect on hepatic drug-metabo-
lizing enzyme systems and not necessarily by 
direct eff€cts on the skin. 
A decrease in the incidence of tumors, induced 
bv DMBA and 1.2,5,6-dibenzanthracene (DBA) 
h~s been found when phenobarbital was applied 
topically and immediately before the carcinogens 
[9]. PhenobarbitaL which had no apparent effect 
on AAH activity, caused a significant reduction in 
the incidence of DBA-induced tumors. This reduc-
tion could not be accounted for by any change in 
the binding of DBA to epithelial cell DNA. In the 
case of DMBA it was thought that the reduction of 
binding to DNA did account for the decrease in 
incidence of tumors. Further studies will be neces-
sary to elucidate the mechanism by which pheno-
barbital alters the appearance of both DBA-in-
duced and DMBA-induced tumors. 
In the current experiments, the dose level of 
DMBA caused some erythema and desquamation. 
lt is possible therefore, that a saturating level of 
the carcinogen resulted from repeated applications 
of DMBA. at the doses used. Irrespective of the 
mechanism, such an effect of high carcinogenic 
doses may explain why phenobarbital was ineffec-
tive when the topical dose of DMBA caused severe 
cutaneous damage. With a reduced oncogenic 
dose. phenobarbital markedly inhibited papil-
lomas at the onset of combined treatment, but the 
effectiveness was diminished or lost with continued 
applications of the carcinogen. These results indi-
cate that the dose levels of DMBA used in the 
fractionated regimens exceeded those levels which 
could be accommodated by the effects of pheno-
barbital. and some incremental amount of the 
carcinogen. or damage. was accrued in the target 
tissue_ which obscured any sustained inhibition. 
The difference in the response of mice in the two 
age groups is consistent with a difference in suscep-
tibility to oncogenesis or to tissue damage. which 
in turn resulted in tumor production. A difference 
in susceptibility to tumorigenesis, however, does 
not appear to be correlated with tissue penetration 
or binding of the carcinogen [10, 11]. It is possible 
that age-dependent differences in the number of 
cells in the phases of the cell cycle are important, 
as it has been shown that tumor susceptibility is 
correlated with the distribution of cells in cycle 
[12.13]. 
An increase in the rate of regression of DMBA-
induced papillomas due to vitamin A administra-
tion has been reported [14]. In the current experi-
ments the reduction of the incidences of papil-
lomas in the groups given dietary phenobarbital 
was not due to any apparent increase in the 
number of papillomas that regressed. 
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Finally, in contrast to studies in liver tumorigen-
esis where phenobarbital caused an acceleration in 
the appearance of hepatic tumors when fed after 
the treatment with the carcinogen [6], the same 
dietary level had no enhancing effect on the 
appearance or frequency of skin tumors. This 
observation was confirmed in an additional series 
of experiments (not shown) in which 24-week-old 
mice received only 2 weekly application of 250 llg 
DMBA and were then placed on the respective 
diets which were maintained for 56 weeks 
It is clear that phenobarbital given concurrently 
with the administration of DMBA inhibited the 
appearance of tumors. The results also suggest 
that the previously reported tumor-enhancing ef-
fect of phenobarbital may be tissue specific. 
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